Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.

Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.

Abstract: Decellularization of tissue by means of an amphipathic solvent a well-established practice. However, situations exist where the provision of enhanced decellularization is preferred. There is a demand for treating methods for coping with such situations. Thus, it is intended to provide a method for enhancing decellularization. The method comprises not only the immersing of a tissue in a solution containing an amphiphilic molecule in non-micellar form (for example, 1,2-epoxide polymer) but also performing a radical reaction (for example, treatment selected from the group consisting of exposure to gamma-ray irradiation, ultraviolet irradiation, a free radical supply source, ultrasonication, electron beam irradiation, and X-ray irradiation).

Abstract: It is a purpose to provide a medicinal-liquid injection apparatus in which a needle-like tubular member is smoothly movable in a lumen without damaging an inner circumferential surface of the lumen. It includes that the needle-like tubular member having an acuminate needle portion as a free end portion thereof, in which a medicinal liquid can flow, is inserted in the lumen of a tubular main body insertable in a body of a living being, and a protection member having a flexible portion provided in a state such that the protection member is movable together with the needle-like tubular member and such that the flexible portion is interposed between an inner circumferential surface of the lumen and a tip of the needle portion of the needle-like tubular member.

Abstract: It is an object of the present invention to provide an infusion device that can be easily inserted into the body and that when inserted into a blood vessel reliably ensures the flow of blood. The infusion device is provided with a needle-shaped tube member having a sharp tip in any one lumen of the three lumens provided within a tubular member that can be inserted into the body in such a manner that it can move axially, an extrusion aperture provided in the tubular member through which the needle-shaped tube member is extruded, and a reagent supplier for supplying a predetermined reagent into the needle-shaped tube member. Additionally, recessed portions extending axially are formed in an outer circumferential surface of the tubular member in such a manner that the cross sectional shape perpendicular to the axial direction of the tubular member is a shape in which at least a portion of the outer circumference of an annular shape has been recessed radially inward.